Marco T. Medina

ORCID: 0000-0003-0469-054X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Epilepsy research and treatment
  • Genetics and Neurodevelopmental Disorders
  • Glycogen Storage Diseases and Myoclonus
  • Parasitic infections in humans and animals
  • Genomics and Rare Diseases
  • Pharmacological Effects and Toxicity Studies
  • Parasite Biology and Host Interactions
  • Mosquito-borne diseases and control
  • Parasites and Host Interactions
  • Neurology and Historical Studies
  • Cerebrospinal fluid and hydrocephalus
  • Acute Ischemic Stroke Management
  • Congenital Anomalies and Fetal Surgery
  • Neurological disorders and treatments
  • Long-Term Effects of COVID-19
  • Genomic variations and chromosomal abnormalities
  • COVID-19 Clinical Research Studies
  • Infectious Encephalopathies and Encephalitis
  • Viral Infections and Vectors
  • Cerebrovascular and Carotid Artery Diseases
  • Malaria Research and Control
  • Neuroscience and Neuropharmacology Research
  • Dementia and Cognitive Impairment Research
  • Health and Medical Education
  • Parasitic Infections and Diagnostics

Memorial Hermann–Texas Medical Center
2024

National Autonomous University of Honduras
2015-2024

World Health Organization
2020-2022

Hospital Regional de Antofagasta
2020-2022

American Association of Neurological Surgeons
2020-2022

Universidad Nacional Hermilio Valdizán
2020

Weatherford College
2020

Public Health Foundation of India
2020

Medical Research Council
2020

Indian Council of Medical Research
2020

BackgroundWorld Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a in patients hospitalized with coronavirus disease 2019 (Covid-19).MethodsWe randomly assigned inpatients Covid-19 equally between one the trial drug regimens that was locally available open control (up to five options, active local standard care). The intention-to-treat primary analyses examined in-hospital...

10.1056/nejmoa2023184 article EN New England Journal of Medicine 2020-12-02

Summary Worldwide, about 65 million people are estimated to have epilepsy. Epidemiologic studies necessary define the full public health burden of epilepsy; set and care priorities; provide information needed for prevention, early detection, treatment; identify education service needs; promote effective support programs with However, different definitions epidemiologic methods complicate tasks these their interpretations comparisons. The purpose this document is consistency in an effort...

10.1111/j.1528-1167.2011.03121.x article EN Epilepsia 2011-09-01

We studied 100 consecutive Mexican patients with epilepsy that started after the age of 25 years. All underwent clinical evaluation, computed tomography, and electroencephalography; additionally, cerebrospinal fluid analysis was performed in 82 them. Neurocysticercosis or its sequelae were diagnosed 50 (50%); 36 these had partial seizures, 41 parenchymal calcifications, 15 two more lesions. Our results are contrast those most studies from countries a low incidence neurocysticercosis, where...

10.1001/archinte.1990.00390140065014 article EN Archives of Internal Medicine 1990-02-01

Summary: Purpose: Determination of epilepsy etiology in population‐based studies is difficult because the high cost diagnostic tests. However, cost‐effectiveness may be proven if preventive public‐health strategies can established from test results. We report an study using clinical and laboratory techniques. Methods: A medical team administered survey to 88% residents by census rural county Salamá, Honduras. Ninety 100 participants identified with active underwent a neurologic examination,...

10.1111/j.0013-9580.2005.11704.x article EN Epilepsia 2005-01-01

The 2001 classification subcommittee of the International League Against Epilepsy (ILAE) proposed to 'group JME, juvenile absence epilepsy, and epilepsy with tonic clonic seizures only under sole heading idiopathic generalized epilepsies (IGE) variable phenotype'. implication is that myoclonic (JME) does not exist as phenotype family members it should no longer be classified by itself or considered a distinct disease entity. Although recognized common form presumed lifelong trait, long-term...

10.1093/brain/awl048 article EN Brain 2006-03-06

The World Health Organization (WHO) International Classification of Diseases (ICD) has been used to classify causes morbidity and mortality such as epilepsy for more than 50 years. aims this critical commentary are do the following: (1) Introduce ICD classification, summarize ICD-9 ICD-10 codes seizures, discuss challenges mapping between these two versions; (2) how relate revised League Against Epilepsy (ILAE) terminology concepts classification seizures epilepsies; (3) ICD-coded data have...

10.1111/epi.12895 article EN Epilepsia 2015-02-12

Summary Albendazole or praziquantel were measured in plasma and cerebrospinal fluid (CSF) 29 patients with neurocysticercosis. Mean levels of albendazole 0.918 μg/ml CSF 0.392 1.640 0.398 CSF, after doses 15 50 mg/kg, respectively. Drug concentrations 43% for 24% praziquantel. The drug obtained both drugs showed ample individual variations that not related to age, sex, presence inflammation the subarachnoid space, therapeutic effectiveness; such seem be due differences pharmacokinetics. Both...

10.1097/00002826-199012000-00008 article EN Clinical Neuropharmacology 1990-12-01

<b>Background: </b> Juvenile myoclonic epilepsy (JME) accounts for 3 to 12% of all epilepsies. In 2004, the GENESS Consortium demonstrated four missense mutations in <i>Myoclonin1/EFHC1</i> chromosome 6p12.1 segregating 20% Hispanic families with JME. <b>Objective: To examine what percentage consecutive JME clinic cases have <i>Myoclonin1/EFHC1</i>. <b>Methods: We screened 44 patients from Mexico and Honduras 67 Japan using heteroduplex analysis direct sequencing. <b>Results: found five...

10.1212/01.wnl.0000313149.73035.99 article EN Neurology 2008-05-27
Coming Soon ...